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Oxidative stress is a hallmark of metabolism-related diseases
and a risk factor for atherosclerosis. FoxO factors have been
shown to play a key role in vascular endothelial development
and homeostasis. Foxo3a can protect quiescent cells from oxi-
dative stress through the regulation of detoxification genes such
as sod2 and catalase. Here we show that Foxo3a is a direct tran-
scriptional regulator of a group of oxidative stress protection
genes in vascular endothelial cells. Importantly, Foxo3a activity
requires the transcriptional co-activator PGC-1, because it is
severely curtailed inPGC-1-deficient endothelial cells. Foxo3a
and PGC-1 appear to interact directly, as shown by co-immu-
noprecipitation and in vitro interaction assays, and are recruited
to the same promoter regions. The notion that Foxo3a and
PGC-1 interact directly to regulate oxidative stress protection
genes in the vascular endothelium is supported by the observa-
tion that PGC-1 transcriptional activity at the sod2 (manga-
nese superoxide dismutase) promoter requires a functional
FoxO site. We also demonstrate that Foxo3a is a direct tran-
scriptional regulator of PGC-1, suggesting that an auto-regu-
latory cycle regulates Foxo3a/PGC-1 control of the oxidative
stress response.
A central question in cardiovascular medicine is how meta-
bolic dysfunctions affect the vascular system and in particular
how they give rise to endothelial oxidative stress. Reactive oxy-
gen species (ROS)6 are normally produced in the mitochondria
as a byproduct of aerobic metabolism. Low levels of ROS have
been shown to play a role in cell signaling (reviewed in Ref. 1)
and to be required for cell proliferation (2). However, oxygen-
free radicals are highly reactive and can damage cellular con-
stituents including proteins, lipids, and DNA, with mitochon-
drial structures being the most susceptible. Excessive
generation of ROS can thus result in altered cellular function,
leading eventually to apoptotic cell death or oncogenic trans-
formation (3).
Excessive generation of mitochondrial ROS has been linked
to aging; neurodegenerative diseases such asAlzheimer disease,
epilepsy, and Parkinson disease; cancer; and vascular disease. In
the vasculature, oxidative stress is associated with metabolic
alterations (diabetes, obesity, and high cholesterol) and results
in endothelial dysfunction. Endothelial dysfunction has in turn
been identified as an early sign of atherosclerosis and its clinical
complications (coronary disease, hypertension, and heart fail-
ure) and is thus considered a common risk factor for many
cardiovascular diseases (4, 5).
Cells have evolved complex antioxidant systems to prevent
excessive accumulation of ROS and consequent cell damage.
Well known examples are catalase and the glutathione system.
Within mitochondria, ROS production is suggested to be pre-
vented by uncoupling proteins (UCP) 2 and 3, the latter mainly
expressed in muscle, and several detoxification enzymes have
been identified, including manganese superoxide dismutase
(MnSOD), peroxiredoxin 3 (Prx3), peroxiredoxin 5 (Prx5), thi-
oredoxin 2 (Trx2), thioredoxin reductase 2 (TrxR2), glutare-
doxin 2a, and glutathione peroxidase 4 (3).
The transcriptional co-activator peroxisome proliferator-
activated receptor  co-activator 1- (PGC-1) is a well char-
acterized positive regulator of mitochondrial function and oxi-
dative metabolism (6). PGC-1 regulates the transcription of a
group of genes involved in ROS detoxification (7). Overexpres-
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sion of PGC-1 in primary endothelial cells reduces ROS levels
and prevents endothelial dysfunction and apoptotic cell death
in response to oxidative stress conditions (8). Consistently,
alterations in PGC-1 levels or activity have been described in
several pathologies associated with oxidative stress conditions
including diabetes, heart disease, and neurological disorders
(9–11).
Another key determinant of ROS homeostasis and endothe-
lial function is theO subfamily of forkhead transcription factors
(FoxO). FoxO factors regulate hormonal, nutrient, and stress
responses and play a key role in endothelial homeostasis, being
necessary for endothelial development and for the induction of
apoptosis to limit angiogenesis (12). Amajor regulator of FoxO
activity is protein kinase B (Akt), which directly phosphorylates
and inactivates FoxO factors, triggering their translocation
from the nucleus to the cytoplasm (13). FoxO family members
activate transcription by specifically binding to apparently
shared binding sites (the consensus sequence is GTAAACA) in
the promoters of target genes (14).
Several lines of evidence suggest a role for FoxO factors in
ROS homeostasis. FoxO-deficient hematopoietic stem cells
contain high concentrations of ROS and show reduced expres-
sion of genes involved in ROS detoxification (12). In particular,
the FoxO factors Foxo3a and Foxo4 have been shown to protect
quiescent cells in vitro from oxidative stress (15) and, in
response to elevated ROS, translocate to the nucleus (16).
Foxo3a has been shown to directly activate transcription of
three important antioxidant enzymes: MnSOD, catalase, and
Prx3 (15, 17, 18).
The role of FoxO factors, in particular Foxo3a, in endothelial
function is an active area of research (12, 19). However, despite
the well established physiological relevance of ROS production
to vascular function, the role of FoxO factors in endothelial
oxidative stress protectionhas not been characterized.Here,we
show that FoxO3a is a direct transcriptional regulator of a
group of oxidative stress protection genes in primary endothe-
lial cells and that this regulation requires PGC-1. We also
show that Foxo3a and PGC-1 interact directly in endothe-
lial cells and propose that these factors cooperate through
this interaction to regulate mitochondrial oxidative stress
protection.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Human umbilical vein endothe-
lial cells (HUVEC), bovine aortic endothelial cells (BAEC),
mouse aortic endothelial cells (MAEC), and mouse embryonic
fibroblasts (MEF) were isolated and cultured as previously
described (20–23). Umbilical cords were obtained from Ruber
International Hospital (Madrid, Spain) with the approval of the
donors and the institutional ethics committee. All of the proto-
cols used conform to the Declaration of Helsinki and the Guide
for the Care and Use of Laboratory Animals published by the
United States National Institutes of Health (publication num-
ber 85-23).
Adenoviral Vectors and Infection—Replication-deficient
adenoviruses expressing PGC-1 or a constitutively active
form of Foxo3a (TM-Foxo3a) under the control of the cyto-
megalovirus promoter have been previously described (8, 24).
Adenovirus generation and purification were as described (8).
HUVEC, MAEC, and MEF were infected with adenoviral vec-
tors at a multiplicity of infection of 1–50 over 6 h. The viruses
were then washed off, and the cells were harvested 48 h post-
infection.mRNAandproteinwere analyzed by real timePCRof
reverse transcribed cDNA (qRT-PCR) and Western blot as
described (25, 26).
Small Interference RNA—Adenovirus expressing small
hairpin RNAs were prepared as described (8) using the
pSilencer adeno 1.0 cytomegalovirus promoter system from
ABI. The cells were infected o/n at a multiplicity of infection of
50 and harvested 24 h post-infection. The oligonucleotides
used were: control: sense, 5-TCGAGCACCAGAGAGC-
TGCCATCCTTCAAGAGAGGATGGCAGCTCTGTGGT-
GTTA-3, and antisense, 5-CTAGTAACACCACAGAGC-
TGCCATCCTTTCTCTTGAAAAGGATGGCAGCTCTG-
TGGTGTT-3; and Foxo3a, sense, 5-TCGAGGAGCTCT-
TGGTGGATCATCTTCAAGAGAGATGATCCACCAAG-
AGCTCTTA-3, and antisense, 5-CTAGTAAGAGCTCT-
TGGTGGATCATCTCTCTTGAAGATGATCCACCAAG-
AGCTCC-3.
Co-immunoprecipitation—Preparation of whole cell extracts
and immunoprecipitation were carried out as described (25).
Chromatin Immunoprecipitation (ChIP)—Experimental
conditions for ChIP were as described previously (8). PGC-1
was immunoprecipitatedwith a polyclonal-PGC-1 antibody
from Santa Cruz Biotechnology and Foxo3a with a mixture of
polyclonal antibodies from Santa Cruz andUpstate. Co-precip-
itated DNA was analyzed by qPCR, using the primer pairs
described (8) and the primers listed below. The -actin gene
was used as a negative control. Catalase, forward, 5-gctgtgta-
actttgggcaagttatt-3, and reverse, 5-cctcccaacaaccctatgagttag-
3; Prx3, forward, 5-acagaagccggaagtctctacct-3, and reverse,
5-tcccactgttttgttaaccttgtg-3; and Trx2, forward, 5-gcaaaatc-
caaaaccacggg-3, and reverse, 5-ccctagaggagggaccggaag-3.
Reactive Oxygen Species Analysis—ROS levels were deter-
mined by flow cytometry using two different fluorochromes. In
the first method, the cells were labeled with 5-chloromethyl-2
7-dichlorodihydrofluorescein diacetate acetyl ester (CM-
H2DCFDA) as described (8). To exclude interference by GFP,
the signal with GFP alone was subtracted from the total signal
obtained for CM-H2DCFDA. In the second method, the cells
were labeled with dihydrorhodamine 6G (DhR6G) as described
(27). To control for changes in the DhR6G signal caused by
variation in mitochondrial membrane potential (m), m
was monitored by flow cytometry analysis of cells labeled with
tetramethylrhodamine methyl ester as described (8).
Promoter Constructs and Luciferase Assays—The 2-kb sod2
promoterconstructwasgeneratedbyPCRamplificationofhuman
genomic DNA, and the product was subcloned into the XhoI site
of pGL3basic (Promega). The point mutation at the IRS site was
introduced with the QuikChange XL site-Directed mutagenesis
kit. The amplification primers were: Sod2-X/f, 5-accgctcgaggact-
tttgtccttccccttgc-3; and Sod2-X/r, 5-accgctcgagaagcaacggaaacg-
gttcagc-3. Themutagenesis primerswere: Sod2m1/f, 5-cttctgac-
gtctgtaaaGaagcccagcccttcc-3; and Sos2m1/r,
5-ggaagggctgggcttCttctttacagacgtcagaag-3.
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The following plasmid constructs have been described pre-
viously: expression vector encoding TM-Foxo3a (non Akt
phosphorylatable Foxo3a) (24); expression vector encoding
PGC-1 (24, 25); the FoxO reporter (PrFx3X) (28); and plas-
mids 5UAS-luc and G4-PGC-1 (29). Plasmids were trans-
fected into BAEC with Lipofectamine 2000TM for 8 h. At 24 h
post-transfection, luciferase activity was determined with the
Dual-luciferase reporter assay system (Promega).
In Vitro Interaction Assays—PGC-1 domains (amino acids
1–186, 1–350, 350–580, and 561–797) were inserted in frame
between the XhoI and NotI sites of pGEX-6P-2 (GE Health-
care) to generate GST-PGC-1 fusions. Recombinant GST
fusion proteins were expressed from pGEX expression vectors
in Escherichia coli Bl21DE3 and were purified using glutathi-
one-agarose (GE Healthcare) according to the manufacturer’s
instructions. The vector containing Foxo3a cDNA under the
control of the T7 promoter has been described (30).
The proteins were labeled with [35S]methionine by in vitro
transcription and translation using the TNT system (Promega).
Labeled proteins were incubated with 1 g of GST fusion pro-
teins immobilized on 20 l of agarose beads in binding buffer
(20 M Tris-HCl, pH 8.0, 10% glycerol, 5 mM MgCl2, 0.5 mM
EDTA, 0.5 mM EGTA, 2 mM dithiothreitol, 0.1–0.4% Nonidet
P-40, 100 mM KCl). Incubation was for 1 h at room tempera-
ture, in binding buffer (final volume, 200 l). The beads were
washed three times with 1ml of binding buffer. Bound proteins
were eluted with Laemmli sample buffer, boiled, and resolved
by SDS-PAGE.
Statistics—The data are expressed as the means  S.D. val-
ues. Statistical significancewas evaluated by analysis of variance
or a nonparametric test, as appropriate. The values were con-
sidered to be statistically significant at p  0.05. n  3 in all
experiments.
RESULTS
Foxo3a Regulates Oxidative Stress Protection Genes in
HUVEC—To investigate the role of Foxo3a in the regulation
of oxidative stress protection genes in endothelial cells, we
infected HUVEC with a recombinant adenovirus encoding a
constitutively active Foxo3a (TM-Foxo3a) or a GFP control
adenovirus (GFP). Analysis of mRNA and protein expression
showed that TM-Foxo3a induced the expression of all oxi-
dative stress genes tested, including well known targets
(MnSOD, catalase, and Prx3) and other previously unchar-
acterized targets such as Prx5, UCP-2, Trx2, and TrxR2 (Fig.
1A). Importantly, TM-Foxo3a also induced the expression of
PGC-1, a general transcriptional regulator of the oxidative
stress protection system. In all cases, increased gene expres-
sion in response to TM-Foxo3a resulted in corresponding
increases in protein content (Fig. 1B). To test whether all
these genes were direct targets of Foxo3a, we carried out
ChIP assays. The primers were directed to promoter regions
that are either “rich” in predicted transcription factor-bind-
ing sites or contain conserved FoxO-like boxes. These exper-
iments showed association of Foxo3a with the promoter
regions of MnSOD, catalase, Prx3, Prx5, UCP-2, Trx2, and
PGC-1. (Fig. 1C). These data suggest that Foxo3a induces a
whole set of mitochondrial antioxidant genes in endothelial
cells and also induces the expression of PGC-1, a transcrip-
tional co-activator that is also a general regulator of the oxi-
dative stress protection system in endothelial cells.
We next tested the impact of Foxo3a on ROS accumulation.
For this, HUVEC were infected with TM-Foxo3a or GFP con-
trol adenovirus, and ROS production was estimated by two
methods. In the first method, the cells were loaded with the
redox-active fluorescent probe DhR6G, and ROS were esti-
FIGURE 1. Foxo3a regulates oxidative stress protection in HUVEC. A, expression of genes involved in oxidative stress protection was determined by
qRT-PCR in HUVEC infected with TM-Foxo3a. Expression is shown as the fold induction above the level in cells infected with control virus (GFP). 18 S RNAwas
used as a loading control. B, Western blot analysis of oxidative stress protection proteins in HUVEC infectedwith TM-Foxo3a or control (GFP) adenovirus. Right
panel, Western blot quantification. C, ChIP analysis of Foxo3a localization in the promoter regions of oxidative stress protection genes in HUVEC infected with
TM-Foxo3a adenovirus.-Actin was used as a negative control. A and C, control samples were assigned the value of 1.D, ROS levels (left panel) andm (right
panel) were determined by fluorescence-activated cell sorting of DhR6G or TMREM loaded HUVEC infected with TM-Foxo3a or control (GFP) adenovirus. A, B,
and D, data are the means S.D. *, p 0.05.
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mated from the fluorescence signal
produced by their interaction with
this probe. DhR6G fluorescencewas
significantly lower in cells express-
ing TM-Foxo3a, indicating a reduc-
tion in ROS accumulation and
therefore suggesting a more active
detoxification system in the pres-
ence of TM-Foxo3a and/or reduced
ROS production (Fig. 1D, left
panel). However, DhR6G is also
sensitive to changes in mitochon-
drial membrane potential (m).
To rule out that the observed
changes were due to differences in
m, we monitored changes in
m independently by loading cells
with the membrane-potential fluo-
rescent probe tetramethylrho-
damine methyl ester. TM-Foxo3a
increased the tetramethylrhodamine
methyl ester signal, indicating that the
reducedDhR6G signalwas not a con-
sequence of altered mitochondrial
membrane potential (Fig. 1D, right
panel). These results were confirmed
by the second method, in which cells
were loaded with the general ROS
probeCM-H2DCFDA (supplemental
Fig. S1).
To evaluate the regulation of
the mitochondrial detoxification
system by endogenous Foxo3a, we
first suppressed Foxo3a expression
in HUVEC, using Foxo3a-specific
small interference RNA. Suppres-
sion of endogenous Foxo3a expres-
sion resulted in reduced mRNA
expression of MnSOD, catalase,
UCP-2, Prx-3, Prx5, Trx2, TrxR2,
andPGC-1, indicating that Foxo3a
is necessary for the maintenance of
the expression of these genes in
endothelial cells (Fig. 2A).
To further investigate the role of
endogenous Foxo3a in the regula-
tion of oxidative stress protection
genes, we next compared their
expression in MEF derived from
Foxo3a/ and Foxo3a/ mice.
As expected, Foxo3a/ MEF
showed reduced basal expression
levels of MnSOD, catalase, UCP-2,
Prx3, Prx5, Trx2, TrxR2, and
PGC-1, supporting the notion
that Foxo3a is a general regulator
of the ROS detoxification system
(Fig. 2B).
FIGURE 2. Requirement of Foxo3a tomaintain oxidative stress protection systems. A, HUVEC were trans-
fected with control or Foxo3a specific small interference RNAs and mRNA expression levels of target genes
were determined by qRT-PCR. B, mRNA expression of oxidative stress protection genes in Foxo3a/ and
Foxo3a/ MEF. 18 S RNA was used as loading control, and MMP13 was used as negative control. Control
samples were assigned the value of 100%. The data are the means S.D. *, p 0.05.
FIGURE 3. PGC-1 induced expression of oxidative stress protection genes is reduced in the absence of
Foxo3a. Up-regulation of oxidative stress protection systems by PGC-1 was determined in Foxo3a/ and
Foxo3a/MEF thatwere infectedwith PGC-1 (Ad-P) or a control adenovirus (Ad).Upper panel, mRNAexpres-
sion levelswere determinedbyqRT-PCR. 18 S RNAwas used as loading control. Control sampleswere assigned
the value of 1. The data are the means S.D. *, p 0.05. Lower panel, Western blot analysis.
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Foxo3a Regulation of Oxidative Stress Protection Genes
Requires PGC-1—These results presented in Figs. 1 and 2
show that both Foxo3a and PGC-1 regulate a common group
of oxidative stress protection genes. Most strikingly, the ChIP
analysis (Fig. 1C, Ref. 8, and supplemental Fig. S2) revealed that
these factors bind to or associate with the same or overlapping
promoter regions. Importantly too, Foxo3a regulates the
expression of PGC-1. Therefore, we aimed to elucidate
whether Foxo3a regulation of oxidative stress protection genes
requires PGC-1 and, if so, whether PGC-1 is working as a
Foxo3a co-activator.
We first tested whether overexpression of PGC-1 could
compensate for Foxo3a deficiency in the regulation of oxidative
stress protection genes. MEF from Foxo3a/ and Foxo3a/
mice were infected with a PGC-1 adenovirus. The ability of
PGC-1 to induce oxidative stress protection genes was
severely impaired in Foxo3a-deficient MEF (Fig. 3), suggesting
that PGC-1 requires Foxo3a to regulate oxidative stress pro-
tection, because PGC-1 overexpression does not compensate
for Foxo3a deficiency. Therefore, Foxo3a induction of PGC-1
expression does not seem to be the only mechanism which
Foxo3a induces oxidative stress protection genes. These
results were supported by the observation that induction of
oxidative stress protection genes by PGC-1 was also
impaired in MEFs infected with an shFoxo3a adenovirus
(supplemental Fig. S3).
To determine whether Foxo3a-mediated induction of the
oxidative protection program was reciprocally dependent on
the presence of PGC-1 or could be mediated by a PGC-1-
independentmechanism,we next analyzed the ability of adeno-
virally expressed TM-Foxo3a to induce oxidative stress protec-
tion genes in MEF and MAEC isolated from PGC-1/ and
PGC-1/ mice. PGC-1/ cells have lower expression of
several oxidative stress protection genes and increased ROS
levels (Ref. 7 and supplemental Fig. S4). Consistently, we found
that the ability of Foxo3a to induce mRNA or protein expres-
sion of all the genes under investigation was either severely
reduced or completely abolished in PGC-1/MEF (Fig. 4, A
and B) andMAEC (Fig. 4, C andD), supporting the notion that
Foxo3a and PGC-1 cooperate to induce the expression of oxi-
dative stress protection genes both in endothelial and nonen-
dothelial cells. However, not all the Foxo3a targets tested were
equally dependent on PGC-1. Notably, although MnSOD
induction seemed to be reduced in PGC-1/ MAEC, the
difference did not reach statistical significance.
Overall MAEC responded more poorly to TM-Foxo3a than
HUVEC or MEF. Although that may be due to an inherent
characteristic of these cells, we think it is more likely to be a
FIGURE 4. Foxo3a-dependent expression of oxidative stress protection genes is reduced in the absence of PGC-1. Induction of oxidative stress protection
genesbyFoxo3awasdetermined inPGC-1/ andPGC-1/MEF (AandB) andMAEC (CandD) thatwere infectedwithTM-Foxo3aor a control adenovirus.Aand
C,mRNAexpressionlevelsweredeterminedbyqRT-PCR.18SRNAwasusedas loadingcontrol.BandD,Westernblotanalysis.Rightpanels,Westernblotquantification.
E, PGC-1/ and PGC-1/MAEC orMEFwere infected with TM-Foxo3a or a control adenovirus, and ROS levels were determined by fluorescence-activated cell
sorting of CM-H2DCFDA loaded cells. Control sampleswere assigned the value of 1. The data are themeans S.D. *, p 0.05.
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consequence of the extended time that these cells have to be in
culture before use, because we have consistently observed rel-
atively poor responses of MAEC to both PGC-1 overexpres-
sion (8) and nitric oxide donor treatment (26). It is also worth
noting that genes whose mRNAs were only slightly induced in
MEF and MAEC by TM-Foxo3a, such as Trx2 and TrxR2,
showed markedly elevated protein levels. Also of interest, in
PGC-1/ cells some proteins were down-regulated by
TM-Foxo3a. Finally, we found that the capacity of TM-Foxo3a
to lower ROS was reduced in the absence of PGC-1 (Fig. 4E).
Foxo3a and PGC-1 Can Interact Directly—To investigate
whether Foxo3a and PGC-1 form part of the same transcrip-
tional complex in endothelial cells, we infectedHUVECwith an
adenovirus expressing PGC-1. Foxo3a was detected in
PGC-1 immunoprecipitates, and the co-immunoprecipita-
tion was significantly enhanced by PGC-1 overexpression
(Fig. 5A). Consistently, PGC-1was detected in Foxo3a immu-
noprecipitates (Fig. 5B).
To confirm the specificity of this interaction, we next carried
out a mammalian two-hybrid assay. BAEC were transiently
transfected with increasing doses of a construct encoding the
Gal4-DBD-PGC-1 fusion protein, in which PGC-1 is fused
to the DNA-binding domain of Gal4 to provide a DNA tether-
ing domain, together with the luciferase reporter plasmid
5UAS-Luc, which contains five copies of the Gal4-binding
site (5UAS) in the promoter region. Co-transfection with a
TM-Foxo3a expression vector significantly increased the tran-
scriptional activity of the promoter (Fig. 5C), supporting the
notion that PGC-1 and Foxo3a can form a functional complex
in endothelial cells.
To determine whether PGC-1 and Foxo3a interact directly
and to identify the PGC-1 domain involved in the interaction,
we generated affinity-purified GST fusion proteins of four
PGC-1 domains (domains A–D) and tested their interaction
in vitro with 35S-radiolabeled Foxo3a (from a reticulocyte
translation system). In the pulldown assays Foxo3a was associ-
ated only with the D domain of PGC-1 (Fig. 5D), correspond-
ing to the C-terminal region (amino acids 580–797).We there-
fore conclude that the association of PGC-1 with Foxo3a in
endothelial cells is likely to be dependent on the direct interac-
tion of these two proteins.
PGC-1-mediated Induction of sod2 Requires a Functional
FoxO Site—Taking into account that Foxo3a and PGC-1
require each other to regulate oxidative stress protection genes
and that these factors seem to be able to interact in cells, we
analyzed whether Foxo3a and PGC-1 could form a functional
complex on their common target genes.We first testedwhether
PGC-1 can work as a co-activator of Foxo3a on FoxO sites by
carrying out transient transfection experiments in BAECwith a
luciferase reporter construct driven by a promoter harboring
three copies of a canonical FoxO binding site (3IRE-luc). We
observed that PGC-1 and Foxo3a could activate this construct
cooperatively (Fig. 6A, left panel), suggesting that PGC-1 is in
fact a Foxo3a co-activator.
To determine whether PGC-1 co-activates Foxo3a on nat-
ural promoters, we tested Foxo3a and PGC-1 co-regulation
on the sod2 promoter, a well characterized target of both fac-
tors.We cloned a 2-kb fragment of the sod2 (MnSOD-encoding
gene) promoter, which contains a well characterized functional
FoxO site, into a luciferase reporter vector. When we co-trans-
fected PGC-1 and TM-Foxo3a expression vectors together
with the wild type sod2 promoter construct, PGC-1 and
Foxo3a were able to cooperate to activate this promoter, sug-
gesting that PGC-1 is a Foxo3a co-activator (Fig. 6A, right
panel).
FIGURE 5. Foxo3a interacts with PGC-1. A, HUVEC were infected with
PGC-1 (Ad-P) or control adenovirus (Ad). PGC-1 was immunoprecipitated
(IP), and Foxo3a was detected in the immunoprecipitated material by West-
ern blotting (WB) but not in a control immunoprecipitation. Input, Western
blot of whole cell lysate. B, HUVEC were infected with a PGC-1 adenovirus
(Ad-P). Foxo3a was immunoprecipitated and PGC-1 was detected in the
immunoprecipitated material by Western blot. C, mammalian two-hybrid
assay. HUVEC were co-transfected with the Gal4 luciferase reporter plasmid
5UAS-Luc, the indicated amounts of G4-DBD-PGC-1 (encoding PGC-1
fused to the DNA-binding domain of Gal4 to provide a DNA tethering
domain), and a TM-Foxo3a expression vector, or the corresponding control
vectors. Luciferase activity was determined 24 h post-transfection. D, GST
pulldown assay mapping the interaction between Foxo3a and PGC-1. GST-
fusions with the indicated PGC-1 fragments (fragments A–D) were immobi-
lized on glutathione beads and incubated with 35S-labeled Foxo3a. After
extensive washing, the samples were separated by SDS/PAGE, and bound
35S-labeled Foxo3a protein was detected by autoradiography.
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To investigate whether PGC-1 activity on sod2 required
functional FoxO sites, a mutant sod2 promoter construct was
generated by introducing a point mutation into the functional
FoxO site. The mutation reduced the basal promoter activity
about 3-fold (Fig. 6B). In transient co-transfection experiments
in BAEC, TM-Foxo3a was able to transactivate the wild type
but not the mutant promoter, as previously described (15).
Importantly, PGC-1 was also able to transactivate wild type
sod2 but not themutant promoter construct. This finding indi-
cates that the functional FoxO site is required for PGC-1-
mediated induction of the sod2 promoter (Fig. 6B).
DISCUSSION
Oxidative stress in the endothelium is a key event in the
development of vascular disease. In this study we show that
Foxo3a regulates a group of oxidative stress protection genes in
vascular endothelial cells and provide strong evidence that the
transcriptional co-activator PGC-1 is a necessary partner of
Foxo3 in the regulation of these genes and that its expression is
directly regulated by Foxo3a (Fig. 7).
Foxo3a Regulates ROS Homeostasis in the Vascular
Endothelium—Although other FoxO factors besides Foxo3a
have been implicated in ROS homeostasis, our loss-of-function
studies show that Foxo3a is necessary for the maintenance of
normal levels of detoxification enzymes, both in primary endo-
thelial cells and MEF. Foxo3a has been previously shown to be
able to directly regulateMnSOD, catalase, and Prx3 (15, 17, 18).
Herewe provide evidence that this regulation also takes place in
the endothelium, and we further show that Foxo3a is also
directly involved in the regulation of Prx5, UCP-2, Trx2 (prob-
ably also TrxR2), and PGC-1. Consistent with the increased
levels of ROS detoxification proteins, cells that express
TM-Foxo3a have reduced levels of ROS.
Previous studies showed that
FoxO factors control endothelial
proliferation and differentiation
processes (31, 32). We show here
that Foxo3a is also required for pro-
tection against oxidative stress in
the endothelium. Understanding
how FoxO controls seemingly dis-
parate pathways such as oxidative
stress protection and induction of a
pro-apoptotic program will be cru-
cial to our understanding of Foxo3a
function in the endothelium and
other systems (33). Therefore, fur-
ther studies to identify proteins that
modulate FoxO target specificity
are warranted.
Foxo3a and PGC-1Are Partners
in the Regulation of ROS Detoxifica-
tion Genes—PGC-1 can coordi-
nately regulate the mitochondrial
oxidative stress protection system
in various cell types including endo-
thelial cells (8). Because PGC-1
cannot bind directly to the pro-
moter sequences of its target genes, it needs a transcription
factor to mediate its protective role. The data presented here
suggest that Foxo3a can be this mediator.
Our results demonstrate that in the absence of PGC-1,
the capacity of Foxo3a to regulate ROS protection genes is
drastically curtailed, an indication that PGC-1 is a neces-
sary partner of Foxo3a in this regulation. Supporting this,
PGC1–1-dependent induction of oxidative stress protec-
tion genes is impaired in the absence of Foxo3a. We propose
that this functional partnership is dependent on the direct
interaction between these two proteins. This hypothesis is
supported by the observations that Foxo3a and PGC-1 can
interact in vitro, that they form part of the same complex,
and that PGC-1 can co-activate Foxo3a. The notion that
this interaction is important for the co-regulation of oxida-
tive stress protection genes is supported by the observation
that both proteins can locate on the same promoter regions
of the co-regulated genes and by the finding that a functional
FoxO site is required for activation of the sod2 promoter by
PGC-1. It is important to note that we cannot extend our
observations to all Foxo3a targets. Indeed, PGC-1 activity
has been reported to inhibit Foxo3a activation of the atro-
gin-1 gene (34).
Although it is currently unknown what signals trigger the
association between Foxo3a and PGC-1, it is interesting
that both Foxo3a and PGC-1 have been shown to be
induced or activated by elevated cell levels of ROS and to be
negatively modulated by two major sensors of metabolic sta-
tus, the PI3K/Akt pathway (13, 35) and the deacetylase SirT1
(36).
Recently, it has been suggested that the orphan nuclear
receptor estrogen-related receptor  plays a role in the reg-
ulation of oxidative stress protection genes by PGC-1 (37).
FIGURE 6. PGC-1 is a co-activator of Foxo3a. A, BAEC were transfected with the FoxO activity luciferase
reporter construct 3IRE-luc (left panel) or with the 2 kb sod2 promoter-luciferase reporter vector (right
panel) and with the indicated amounts of Foxo3a and PGC-1 expression vectors or the corresponding
controls. B, BAEC were transfected with the wild type 2-kb sod2 promoter (wt) or version containing a
point mutation in the functional FoxO site (mut) and with the indicated amounts of expression vectors
encoding Foxo3a (left panel) or PGC-1 (right panel) or the corresponding controls. Luciferase activity was
determined 24 h post-transfection. Control samples were assigned the value of 1. The data are the
means  S.D. *, p  0.05.
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It will thus be interesting to see whether estrogen-related
receptor  plays a role in the formation of a Foxo3aPGC-
1 complex or works through a Foxo3a-independent
mechanism.
An understanding of how the response to oxidative stress
is orchestrated requires knowledge not only of the transcrip-
tion factors involved but also of how their levels and activi-
ties are modulated in response to oxidative stress. It has been
reported that Foxo3a nuclear localization is increased under
oxidative stress conditions (38) and that PGC-1 expression
is induced by H2O2 via activation of cAMP-responsive ele-
ment-binding protein (7). Our finding that Foxo3a is also a
direct transcriptional regulator of PGC-1 suggests that
activation of PGC-1 under stress conditions could be also
elicited via Foxo3a.
Metabolic disorders usually affect the physiology of the
vascular endothelium and result in oxidative stress (39).
Here we show that both PGC-1 and Foxo3a are likely to be
key players in the interplay between metabolic control and
oxidative stress protection in the vascular endothelium.
Understanding the key signals and components of this reg-
ulatory pathway may identify new targets for pharmacolog-
ical intervention in cardiovascular diseases associated with
metabolic disorders.
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